PT97905B - Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina - Google Patents
Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina Download PDFInfo
- Publication number
- PT97905B PT97905B PT97905A PT9790591A PT97905B PT 97905 B PT97905 B PT 97905B PT 97905 A PT97905 A PT 97905A PT 9790591 A PT9790591 A PT 9790591A PT 97905 B PT97905 B PT 97905B
- Authority
- PT
- Portugal
- Prior art keywords
- cystine
- diacetyl
- ester
- diseases
- active ingredient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims abstract description 9
- 210000000987 immune system Anatomy 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims description 31
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 11
- 206010006451 bronchitis Diseases 0.000 claims description 11
- 208000007451 chronic bronchitis Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229960003067 cystine Drugs 0.000 claims description 9
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 239000004158 L-cystine Substances 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- NXPNPYNCKSWEHA-WDSKDSINSA-N methyl (2r)-2-amino-3-[[(2r)-2-amino-3-methoxy-3-oxopropyl]disulfanyl]propanoate Chemical compound COC(=O)[C@@H](N)CSSC[C@H](N)C(=O)OC NXPNPYNCKSWEHA-WDSKDSINSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 10
- 241000042812 Divales Species 0.000 description 8
- 229960004308 acetylcysteine Drugs 0.000 description 8
- 230000005284 excitation Effects 0.000 description 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- -1 radical superoxide Chemical class 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- YTPQSLLEROSACP-UHFFFAOYSA-N 2-acetamido-3-[(2-acetamido-2-carboxyethyl)disulfanyl]propanoic acid Chemical compound CC(=O)NC(C(O)=O)CSSCC(C(O)=O)NC(C)=O YTPQSLLEROSACP-UHFFFAOYSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000006025 oxidative dimerization reaction Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- YTPQSLLEROSACP-YUMQZZPRSA-N (2R)-2-acetamido-3-[[(2R)-2-acetamido-2-carboxyethyl]disulfanyl]propanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSSC[C@@H](C(O)=O)NC(C)=O YTPQSLLEROSACP-YUMQZZPRSA-N 0.000 description 1
- OUNCXWQAJOLCDW-UWVGGRQHSA-N (2r)-2-(butanoylamino)-3-[[(2r)-2-(butanoylamino)-2-carboxyethyl]disulfanyl]propanoic acid Chemical compound CCCC(=O)N[C@H](C(O)=O)CSSC[C@@H](C(O)=O)NC(=O)CCC OUNCXWQAJOLCDW-UWVGGRQHSA-N 0.000 description 1
- ZLCOWUKVVFVVKA-WDSKDSINSA-N (2r)-3-[[(2r)-2-acetamido-2-carboxyethyl]disulfanyl]-2-aminopropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSSC[C@H](N)C(O)=O ZLCOWUKVVFVVKA-WDSKDSINSA-N 0.000 description 1
- CVBVDRNGIPXSLU-RYUDHWBXSA-N (2r)-3-[[(2r)-2-carboxy-2-(3-methylbutanoylamino)ethyl]disulfanyl]-2-(3-methylbutanoylamino)propanoic acid Chemical compound CC(C)CC(=O)N[C@H](C(O)=O)CSSC[C@@H](C(O)=O)NC(=O)CC(C)C CVBVDRNGIPXSLU-RYUDHWBXSA-N 0.000 description 1
- SJHPCNCNNSSLPL-NTMALXAHSA-N (4z)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)/N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-NTMALXAHSA-N 0.000 description 1
- 241001222157 Amblyospora stimuli Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
PROCESSO PARA A PREPARAÇÃO DE COMPOSIÇQES FARMACÊUTICAS
CONTENDO DERIVADOS DA CISTINA
Campo da invenção
A presente invenção diz respeito a uma nova utiH zação clínica de N,N' -diacetilcistina, N,N’-dibutirilcistina,N,N’-diisovalerilcistina, Ν,Ν*-dicapri1ilcistina, éster metílico da Ν,Ν1-diacetilcistina, éster etílico Ν,Ν*-diacetilcistina e éster dimetílico da Ν,Ν'-diisovalerilcistina nas formas racémicas ou na forma de isómeros D ou L ópticos.
A presente invenção diz especialmente respeito à utilização dos compostos citados antes na preparação de medicamen_ toscomacção imunomodeladora, especialmente acção imunoestimul ado.
ra.
Antecedentes da invenção
A N-aceti1-L-cisteína é um composto amplamente uti. lizado no tratamento de doenças obstrutivas crónicas do tracto res piratório/bronquite crónica( para mais referências consultar Mui
ticentre Study Group. Long-term oral acetilcysteine in chronic bronchitis. A double-bl ind controlled Study 11 Eur. J. Respir. Dis. 1980, 61 (supl. 111), 93-108; Boman, G., Backer, u., Larsson, S., Melander, B., e Wahlander, L. Oral acetylcysteine reduces exacer bation rate in chronic bronchitis. Reoort of a trial organized by the Swedish Society for Pulmonary Disease Eur. J. Respir. Dis. 1983, 64, 405-415; e British Thoracic Society Research Committee Oral N-acetylcysteine and exacerbation rates in patients with chro nic bronchitis and severe airway obstruction Thorax 1985,40,832-835). Ainda não se descobriu o mecanismo de acção deste composto; a sua acção tem sido atribuída a propriedades mucolíticas (consultar Multicentre Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study Eur. J. Respir. Dis. 1980, 61 (supl. 111), 93-108; Boman, G., Backer, U., Larsson, S., Melander, B., e Wahlander, L-Oral acetylcysteine redu_ ces exacerbation rate in chronic bronchitis. Report of a trial organized by the Swedish Society for Pulmonary Disease Eur. J. Respir. Dis, 1983, 64, 405-415 ; e British Thoracic Society Research Committee Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airway obstruction Thorax 1985,40, 832-835), propriedades anti-oxidantes (consultar Aruoma, 0.1., Halliwell, B.s Hoey, B.M., e Butler, J.Free Radical Biol.Med. 1989,6, 593-597) e também propriedades imunomodeladoras (consultar Bergstrand, H., Bjõrnson, A., Eklund, A., Hernbrand, R., Eklund,
A., Larsson, K., Linden M., e Nilsson, A. Stimuli-induced superoxide radical generation in vitro by human alveolar macrophages from Smokers; Modulation By N-Acetylcysteine treatment in vivo J. Free
-3Radicals Biol. & Med. 2, 1986, 119-127).
A presente invenção diz respeito ao dissulfureto da N-acetilcisteína que é a Ν,Ν1-diaceti lcistina ( seguidamente desi£ nada por DiNAC), isto é, o composto de fórmula
COOH s-ch9-ch-nh-coch„
I
S-CH2-CH-NH-C0CH3
COOH â Ν,Ν*-dibutirilcistina ( seguidamente designada por diBUT), isto é, o composto de fórmula
COOH
I
S-CH -CH-NH-COCH0CH CH_ | 2 2 2 3
S-CHo-CH-NH-C0CH -CHOCH 2 | 2 2 3
COOH à N, N1 -di i sovaler i 1 c i st i na ( seguidamente designada por diVAL), i_s to é, o composto de fórmula
-4COOH CH3
S-CH0-CH-NH~COCH_CHCH~ | Z á i
S-CH2-CH-NH-C0CH2CHCH3
COOH CH3 à N,N*-dicapri1i1cistina ( seguidamente designada por diCAP), isto é, o composto de fórmula
COOH
I
S-CH2-CH-NH-C0-(CH2)6CH3
S-CH2-CH-NH-C0-(CH2)5CH3
COOH ao éster dimetílico da Ν,Ν1-diacetilcistina (seguidamente designado por DiMeNAC), isto é,o composto de fórmula:
COOCH,
I
S-CH2-CH-NH-C0CH3
S-CH2-CH-NH-C0CH3
C00CH3 ao éster díetílico da Ν,Ν’-diacetilcistina ( seguidamente designada por diEtNAC), isto é, o composto de fórmula
COOC0H, | 2 5
S-CH2-CH-NH-C0CH3
S-CH9-CH-NH-COCHq
I
COOC.H.
□ ao éster dimetílico da Ν,Ν*-diisovalerilcistina ( seguidamente de. signado por diMeVAL), isto é, o composto de fórmula
COOCH- CH.
I I3
S-CH2-CH-NH-C0CH2-CHCH3
S-CHo-CH-NH-C0CHo-CHCHI
C00CH3 CH3
A presente invenção diz respeito aos compostos cita, dos antes na forma racémica bem como às formas D e L isoméricas dos mesmos compostos. Particularmente importantes são os compostos com a configuração L, em especial a Ν,Ν1-diaceti1-L-cistina.
A presente invenção também diz respeito a compostos sob a forma de sais aceitáveis sob o ponto de vista fisiológico tais como os sais de sódio, potássio, amónio, cálcio ou magnésio. Inclui também sais dos compostos diNAC, diBUT, diVAL e diCAP derivados de bases orgânicas aceitáveis sob o ponto de vista farmacêutico.
Os compostos citados antes foram, anteriormente à presente invenção, descritos em patentes de invenção bem como em trabalhos científicos como, por exemplo, o composto DiNAC nas publicações seguintes: patente de invenção norte-americana N2 4827016: patente de invenção europeia N2 300 100; patente de invenção norte-americana N2 4724239; patente de invenção norte-americana N2 4708965; patente de invenção alemã N2 2326444; Wilson, I.D., e Nicholson, J.K. Analysis of thiols and disulfides in Sulphur-con. taining drugs and related organic compounds Chemistry, Biochemistry and Toxicology ( ed. L.A. Damani) Vol. 2A. ; Analytical. biochemical and toxicological aspects of sulphur xenobiochemistry
Ellis Horwood Series in biochemical Pharmacology ( Halstred Press: a division of John Wiley & Sons ) Chichester 1989, p. 45; e Sjõdin K., Nilsson E., Hallberg, A., e Tunek, A. Metabolism of N-Acetyl-L-Cysteine. Some structural requirements for the deacetyla. tion and consequences for the oral bioavailability Biochem. Pharmacol. 1989, 38, 3981-3985). Na patente de invenção norte-americana N2 4 827 016 este composto é reivindicado como eficaz no tratamento tópico de inflamações dérmicas induzidas e propagadas
-Ί-
por leucotrienos.
Os compostos restantes foram também descritos em trabalhos científicos. £ consultar, por exemplo, para o diMeNAC: Bowman, W.R. Richardson, G.D. Tetrahedron Lett. 1981, 22, 1551-1554; para o diEtNAC: Damico, R.A. Boggs, R.W. patente de invejn ção norte-americana NQ 3 952 115 (1976) ; para o diVAL e o diMeVAL: Martin, T.A. J. Med. Chem. 1969, 12, 950-953); para o diCAP: patente de invenção francesa 8205M ; para o diBUT: patente de invejn ção francesa 2503151J.
Não existem relatos ou informação geral respeitante às propriedades farmacológicas e/ou terapêuticas destes compos, tos relativamente aos sistemas imunológicos ou doenças inflamatórias dos pulmões como, por exemplo,a bronquite crónica.
Descrição da invenção
Inesperadamente observou-se que os compostos diNAC, diBUT, diVAL, diCAP, diMeNAC, diEtNAC e diMeVAL citados antes na presente memória descritiva e utilizados numa experiência com anj. mais para avaliar a reactividade de células T in vivo, isto é,numa reacção de hipersensibi1 idade do tipo retardado no ouvido de um rato, são agentes imunoestimuladores muito potentes e eficientes, sendo alguns 100 a 1000 vezes mais eficazes do que o tiol-NAC.
Nesta experiência os compostos são agentes imunoestimuladores mui_ to eficazes com uma potência e eficácia superior ou igual à de agentes imunoestimuladores conhecidos tais como ditiocarbamato de dietilo (DTC) ou dissulfureto de hidroxietilo ( HEDS ) /Γconsultar St Georgiev, V. New Synthetic immunodulating agents. Trends in Pharmacological Science 1988, 446-451 J.
Consequentemente, os compostos DiNAC, diBUT, diVAL, diCAP, diMeNAC, diEtNAC, diMeVAL e os seus isómeros ópticos D e L podem utilizar-se no tratamento de doenças em que se suspeita ou se está na presença de uma deficiência do sistema imunitário e/ou de um sistema defensivo ineficaz do hospedeiro.
Exemplos destas doenças são a bronquite crónica e outras doenças inflamatórias do tracto respiratório tais como asma e rinite bem como certas formas de doenças autoimunes tal como a diabetes e a artrite reumatóide e/ou doenças malignas diversas.
A infecção por HIV ou SIDA, pode tratar-se com estes compostos, também a aterosclerose se pode tratar com estes compostos.
As quantidades eficazes dos compostos diNAC, diBUT, diVAL, diCAP, diMeNAC, diEtNAC, diMeVAL e os correspondentes isómeros ópticos D e L para o tratamento das doenças mencionadas atrás estão compreendidas dentro da gama de dose diária 0,5-500 mg, de preferência 5-50 mg.
-9/
Síntese dos compostos
Os compostos diNAC, diBUT, diVAL e diCAP podem pr£ parar-se, por exemplo, a partir da L-cistina por acilação ( consultar patente de invenção norte-americana NQ 4827016; patente de invenção europeia 300 100; patente de invenção norte-americana N- 4 724 239; patente de invenção norte-americana 4 708 965; patente de invenção alemã 2 326 444; Marshall, R. Winitz, M., Birnbaum, S.M. e Greenstein, J.P. J. Am. Chem. Soc. 1957, 79, 4538-4544; e Cecil, R. McPhee, J.B. Biochem. J. 1957, 66, 538-543 )ou através de uma dimerização oxidativa das acilcisteínas apropriadas ( consultar Snow, J.T., Finley, J.W. Friedman, M. Biochem.Biophys. Res. Commun. 1975, 64, 441-447).
Os ésteres diMeNAC, diEtNAC e diMeVAL podem sintetizar-se de um modo análogo, isto é, por acilação dos ésteres etí lico ou metílico da cistina quando conveniente ou por dimerização oxidativa dos ésteres etílico ou metílico respectivos da N-acetil-cistina ou do éster metílico da N-isovalerilcisteína. Relativameii te aos exemplos destas preparações consultar Bonnett, R., Nicolaidow, P.J. Chem. Soc. Perkin Trans. I 1979, 1069-1077; Schaad L.J., Werner, R.M., Dillon, L. Field, L., Tate, C.E. J. Med. Chem. 1975, 18, 344-351 e Martin, T.A. J. Med. Chem. 1969, 12, 950-953.
Efeitos dos compostos num modelo de hipersensibilidade do tipo retardado no rato
A capacidade dos compostos diNAC, diBUT, diVAL, diCAP, diMeNAC, diEtNAC e diMeVAL para estimular respostas imuni. tárias é ilustrada através da sua eficácia num modelo de reacção de hipersensibilidade do tipo retardado ( DTH ) no rato.
Utilizaram-se ratos Balb/c machos e fêmeas fornecj_ dos por Bomholtsgaard ( Dinamarca ) e Charlie Rivers ( Inglaterra) com um peso compreendido entre 18 e 20 g. Neste ensaio utilizou-se como antigénio a 4-etoximetileno-2-feniloxazolona ( OXA ) fornecida por BDH ( Inglaterra).
Sensibilizaram-se os ratos, Dia 0, por aplicação epicutânea de 150 jjI de uma solução etanol absoluto-acetona ( 3:1 ) contendo 3% de OXA no abdómen e tórax barbeados. 0 tratamento com a forma L de diNAC, diMeNAC, diEtNAC, diMeVAL ou o veículo (tampão de fosfato pH 7,0 ) iniciou-se por ingestão oral imediatamente após a sensibilização e prosseguiu uma vez por dia até ao Dia 6. Sete dias (Dia 6) após a sensibilização estimularam-se ambos os ouvidos de todos os ratos nos dois lados por aplicação tópica de 20 jil de OXA a 1% dissolvidos em óleo de amendoim.Mediu-se a espessura do ouvido an. tes e 24 ou 48 após a excitação utilizando uma craveira de mola Oditest. A excitação e a medição realizaram-se sob anestesia ligeira com pentobarbital. A intensidade das reacções de hipersensibilidade
-11c τ τ do tipo retardado exprimiram-se de acordo com t24/48 - to unidades jLim em que ^o, ^24 e ^48 representam a espessura do ouvido antes de 24 ou 48 após a excitação, respectivamente, num ensaio individual ( T ), Os resultados exprimiram-se como o +/- E.P.M. médio. 0 nível de significância entre médias dos grupos obteve-se pelo teste t de cauda dupla de Student. Os Quadros 1 e 2 mostram os resultados das medições feitas às 24 e 48 horas, respectivamente, a partir de uma experiência característica com a forma L do diNAC. Os resultados mostram que o L-diNAC provocou, após administração oral, um aumento significativo da espessura do ouvido sendo por assim dizer a resposta proporcional à conceii tração.
QUADRO 1
Espessura do com as doses | ouvido 24 indicadas | horas após de L-diNAC | a excitação de ou veículo. | animais tratados |
Cone. yumo 1 / kg | N | Dif. T -T t24 to | E.P.M. | Sign. |
tampão | 13 | 7,85 | 0,32 | |
NaCl | 10 | 7,90 | 0,30 | s. s. |
0,03 | 10 | 13,75 | 0,47 | *** |
0,30 | 10 | 15,70 | 0,48 | *** |
3,0 | 10 | 18,30 | 1,02 | *** |
30,0 | 15 | 20,67 | 0,67 |
***: ρ<0,001
QUADRO 2
Espessura do ouvido 48 horas após a excitação de | animais tratados Sign. | |||
com as doses Cone. ^umol/Kg | indicadas de L-diNAC ou veículo | |||
N | Dif. T -T t48 to | E.P.M. | ||
tampão | 14 | 9,64 | 0,35 | |
NaCl | 10 | 9,85 | 0,54 | s .s . |
0,03 | 10 | 11,65 | 0,27 | *** |
0,30 | 10 | 12,65 | 0,48 | *** |
3,0 | 10 | 14,95 | 0,55 | *** |
30,0 | 15 | 13,63 | 0,30 | *** |
***: pZ 0,001
Quadro 3 apresenta os números correspondentes ã espessura do ouvido 24 e 48 horas após a excitação dos animais tratados com diMeNAC e diEtNAC.
QUADRO 3
Espessura do ouvido 24 e 48 horas após a excitação de animais tratados com as formas L do diMeNAC e diEtNAC
Cone yjmo 1 / Kg | N | Dif. T -T t24 ‘to | E.P.M. | Sign. | |
tampão | 24 h | 10 | 8,70 | 0,34 | |
diMeNAC | 0,03 | ' 10 | 18,00 | 0,84 | #** |
3,0 | 10 | 12,55 | 0,88 | ** | |
diEtNAC | 0,03 | 10 | 11,75 | 0,62 | *** |
3,0 | 10 | 13,05 | 0,59 | *** | |
diMeNAC | 48 h 0,03 | 10 | 12,85 | 0,67 | ** |
3,0 | 10 | 13,35 | 0,67 | *** | |
diEtNAC | 0,03 | 10 | 13,15 | 0,53 | **# |
3,0 | 10 | 13,20 | 0,66 | *** |
** : PZ 0,01 ***: p^ 0,001
Composigões farmacêuticas
As substâncias activas descritas podem incluir-se em formas de dosagem diferentes como, por exemplo, comprimidos eventualmente revestidos, cápsulas de gelatina, soluções e aerossóis.
Para a preparação de comprimidos eventualmente reves tidos e cápsulas de gelatina as substâncias activas podem associar-se com materiais aceitáveis sob o ponto de vista farmacêutico co mo, por exemplo, lactose, amido, fosfato dicãlcico, celulose microcristalina, polivinilpirrolidona, gelatina, derivados da celu lose, dióxido de sílica coloidal, talco e ácido esteárico ou os seus sais.
Para a preparação de soluçoes orais os excipientes apropriados são a água, a glucose, o sorbitol, a frutose e o xili tol.
As formas de dosagem podem além dos excipientes meneio nados conter agentes conservantes, estabilizantes, reguladores da viscosidade, emulsionantes, edulcorantes, corantes, aromatizantes, reguladores da tonicidade, tampões ou anti-oxidantes. Podem conter também outras substâncias importantes sob o ponto de vista terapêutico.
Comprimidos contendo 10 mg de substância activa por comprimidos:
Exemplo 1
Substância activa | 10 mg |
Lactose | 100 mg |
Amido de batata | 50 mg |
Polivinilpirrolidona | 5 mg |
Celulose microcristalina | 15 mg |
Estearato de magnésio | 1 mg |
Exemplo_2
Comprimidos de compressão directa contendo 5 mg de substância activa por comprimido:
Substância activa | 5 mg |
Lactose anidra | 150 mg |
Celulose microcristalina | 50 mg |
Dióxido de sílica coloidal | 1 mg |
Estearato de magnésio | 2 mg |
Eventuaimente, os comprimidos obtidos podem revestir-se com uma película de, por exemplo, hidroxipropilmetilcelulose,
hidroxipropilcelulose ou copolímero do éster de ãcido dimetilamino eti1-metacrilato-metacrí1ico.
Exemplo 3
Solução injectâvel contendo 1mg/ml de substância activa.
Substância activa 1,0 mg
Cloreto de sódio 8,8 mg
Agua para injectáveis q.b.p. 1 ml
Exemplo 4
Solução oral contendo 1 mg/ml de substância activa
Substância activa | 1,0 ml |
Sorbitol | 150,0 mg |
G1icerina | 100,0 mg |
Edetato dissódico | 0,5 mg |
Agente conservante q.b. Agente aromatizante q.b Agua purificada
q.b.p.
ml
Exemplo 5
Aerossol em pó contendo 1 mg por dose.
Acondiciona-se a substância activa micronizada a um
D inalador para pós como, por exemplo um Turbuhaler proporcionando 1 mg/dose.
Claims (4)
1,- Processo para a preparação de composições farmacêuticas apropriadas para o tratamento de doenças devidas a defeitos no sistema imunitário como, por exemplo, bronquite cró nica, asma, rinite, diabetes, artrite reumatóide, doenças maliçf nas, inf ecções por HIV/SIDA ou doenças aterosclerõticas em mamí feros incluindo o homem, caracterizado pelo facto de se misturar, como ingrediente activo, uma quantidade eficaz sob o ponto de vista terapêutico, compreendida por exemplo entre 1 mg e 10 mg, de um dos compostos racémicos Ν,Ν'-diacetilcistina, Ν,Ν'-dibutirilcistina, N,N'-diisovalerilcistina, N,N'-dicaprililcistina, éster dimerílico da Ν,Ν'-diacetilcistina, éster dietílico da Ν,Ν'-diacetilcistina e éster dimetílico da N,N'-diisovalerilcistina com acção imunomodeladora, dos seus isõme-19- ros ópticos D e L ou dos seus sais aceitáveis sob o ponto de vi£ ta fisiológico, com um veículo aceitável em farmácia.
2. - Processo de acordo com a reivindicação 1, carac terizado pelo facto de se utilizar, como ingrediente activo, um isomero óptico L de Ν,Ν'-diacetilcistina, N,N'-dibutirilcistina, Ν,Ν'-diisovalerilcistina, N,N’-dicaprililcistina, éster dimetíli co da Ν,Ν’-diacetilcistina, éster dietílico da N,N'-diacetilcistina ou éster dimetílico da Ν,Ν’-diisovalerilcistina ou um seu sal aceitável sob o ponto de vista fisiológico.
3. - Processo de acordo com a reivindicação 1, carac terizado pelo facto de se utilizar como ingrediente activo a
Ν, N'-diacetil-L-cistina.
4. - Método para o tratamento de doenças devidas a defeitos no sistema imunitário como, por exemplo, bronquite crónica, asma, rinite, diabetes, artrite reumatóide, doenças malignas, infecções por HIV/SIDA ou doenças aterosclerõticas em mamíferos incluindo o homem, caracterizado pelo facto de se adminis trar, a um hospedeiro necessitado de um tal tratamento, uma quan tidade eficaz, compreendida entre 0,5 e 500 mg/dia, de um dos compostos racémicos Ν,Ν'-diacetilcistina, N,N’-dibutirilcistina, Ν,Ν'-diisovalerilcistina, N,N*-dicaprililcistina, éster dimetíli co da Ν,Ν'-diacetilcistina, éster dietílico da N,N'-diacetilcis-20 tina e éstsr dimetílico da N,Ν’-diisovalerilcistina ccm acção imunomodeladora, dos seus isómeros ópticos D e L ou dos seus sais aceitáveis sob o ponto de vista fisiológico, como ingredien te activo, em associação com um veículo aceitável em farmácia.
O Agente Oficial da Propriedade Industrial
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9002067A SE9002067D0 (sv) | 1990-06-08 | 1990-06-08 | The pharmacological use of certain cystine derivatives |
SE9002275A SE9002275D0 (sv) | 1990-06-28 | 1990-06-28 | Novel 3,3'-dithiobis(propionic acids) |
Publications (2)
Publication Number | Publication Date |
---|---|
PT97905A PT97905A (pt) | 1992-03-31 |
PT97905B true PT97905B (pt) | 1998-10-30 |
Family
ID=26660796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97905A PT97905B (pt) | 1990-06-08 | 1991-06-07 | Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina |
Country Status (20)
Country | Link |
---|---|
US (2) | US5441976A (pt) |
EP (1) | EP0532595B1 (pt) |
JP (1) | JP3204320B2 (pt) |
KR (1) | KR100236253B1 (pt) |
AT (1) | ATE144705T1 (pt) |
AU (1) | AU652946B2 (pt) |
CA (1) | CA2083274C (pt) |
DE (1) | DE69122961T2 (pt) |
DK (1) | DK0532595T3 (pt) |
HK (1) | HK62597A (pt) |
HU (1) | HU215920B (pt) |
IE (1) | IE80754B1 (pt) |
IL (1) | IL98310A (pt) |
LV (2) | LV10186B (pt) |
NO (1) | NO924723L (pt) |
NZ (1) | NZ247658A (pt) |
PT (1) | PT97905B (pt) |
RU (1) | RU2119793C1 (pt) |
SG (1) | SG49736A1 (pt) |
WO (1) | WO1991018594A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9018994D0 (en) * | 1990-08-31 | 1990-10-17 | Secr Defence | Toxic agent protective compounds |
US5889050A (en) * | 1991-06-21 | 1999-03-30 | Astra Aktiebolag | 3,3'-dithiobis (propionic acids) and esters thereof |
SE9103572D0 (sv) * | 1991-11-29 | 1991-11-29 | Astra Ab | Organic salts of n,n'-diacetyl cystine |
JP2947044B2 (ja) * | 1993-01-27 | 1999-09-13 | 味の素株式会社 | 免疫不全症候群治療の補助療法剤 |
DE4329857C2 (de) * | 1993-09-03 | 1995-08-24 | Deutsches Krebsforsch | Verbindung zur Stärkung des Immunsystems und von Immunreaktionen |
SE9500897D0 (sv) * | 1995-03-14 | 1995-03-14 | Astra Ab | The pharmacological use of certain cystine derivatives |
SE9501067D0 (sv) * | 1995-03-24 | 1995-03-24 | Astra Ab | New peptides |
SE9602262D0 (sv) * | 1996-06-06 | 1996-06-06 | Astra Ab | New use of derivatives of cystine |
US6197749B1 (en) * | 1997-10-29 | 2001-03-06 | Ajinomoto Co., Inc. | Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes |
US20030203006A1 (en) * | 1997-10-29 | 2003-10-30 | Ajinomoto Co. Inc. | Immunomodulator |
CN100453531C (zh) | 1998-10-09 | 2009-01-21 | 味之素株式会社 | 半胱氨酸衍生物 |
EP1004302A3 (en) * | 1998-10-29 | 2003-06-04 | Ajinomoto Co., Inc. | Immunomodulator |
SE9900438D0 (sv) * | 1999-02-10 | 1999-02-10 | Astra Ab | The pharmacological use of certian cystine derivatives |
JP3988014B2 (ja) * | 2000-02-02 | 2007-10-10 | 味の素株式会社 | ウイルス感染症予防剤 |
DK2283817T3 (en) | 2000-11-30 | 2016-09-05 | Vectura Ltd | Process for preparing particles for use in a pharmaceutical composition |
SE518784C2 (sv) * | 2000-12-27 | 2002-11-19 | Nactilus Ab | "N-Acetyl-L-cystein med kompositioner för behandling av neoplasier" |
US8530509B2 (en) | 2003-06-20 | 2013-09-10 | Siga Technologies, Inc. | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
DE102004043055B4 (de) | 2004-09-06 | 2009-04-02 | Siemens Ag | Führungsvorrichtung zur Führung eines bewegbaren Maschinenelementes einer Maschine |
KR20090083891A (ko) * | 2006-10-03 | 2009-08-04 | 갈레온 파마슈티칼스 | S-니트로소티올 화합물 및 관련 유도체 |
EP3006425A1 (en) * | 2007-04-23 | 2016-04-13 | Siga Technologies, Inc. | Pharmaceutical composition for use in the treatment and prevention of orthopoxvirus infections and associated diseases |
US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
ES2613729T3 (es) | 2008-02-07 | 2017-05-25 | Marquette University | Cisteína y profármacos de cisteína para tratar la esquizofrenia y reducir los deseos compulsivos por los fármacos |
WO2015163488A1 (en) | 2014-04-25 | 2015-10-29 | Ajinomoto Co., Inc. | Immunostimulating agent |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR8205M (pt) * | 1968-12-20 | 1970-09-14 | ||
US3878305A (en) * | 1972-05-25 | 1975-04-15 | Procter & Gamble | Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids |
US3952115A (en) * | 1975-04-02 | 1976-04-20 | The Procter & Gamble Company | Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters |
GB2097256B (en) * | 1981-04-02 | 1985-05-30 | Morelle Jean V | Compositions containing n-butyryl alphaaminoacids |
FR2503151A1 (fr) * | 1981-04-02 | 1982-10-08 | Morelle Jean | Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux |
US4724239A (en) * | 1985-09-16 | 1988-02-09 | Morgan Lee R | Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine |
US4827016A (en) * | 1985-09-16 | 1989-05-02 | Morgan Lee R | Method and compounds for reducing dermal inflammations |
US4708965A (en) * | 1985-09-16 | 1987-11-24 | Morgan Lee R | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives |
IT1249650B (it) * | 1991-05-29 | 1995-03-09 | Poli Ind Chimica Spa | N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico |
-
1991
- 1991-05-30 IL IL9831091A patent/IL98310A/en not_active IP Right Cessation
- 1991-06-03 WO PCT/SE1991/000388 patent/WO1991018594A1/en active IP Right Grant
- 1991-06-03 CA CA002083274A patent/CA2083274C/en not_active Expired - Fee Related
- 1991-06-03 AT AT91910813T patent/ATE144705T1/de not_active IP Right Cessation
- 1991-06-03 HU HU9203871A patent/HU215920B/hu not_active IP Right Cessation
- 1991-06-03 RU RU92016463A patent/RU2119793C1/ru not_active IP Right Cessation
- 1991-06-03 DK DK91910813.4T patent/DK0532595T3/da active
- 1991-06-03 JP JP51096391A patent/JP3204320B2/ja not_active Expired - Fee Related
- 1991-06-03 SG SG1996004501A patent/SG49736A1/en unknown
- 1991-06-03 DE DE69122961T patent/DE69122961T2/de not_active Expired - Fee Related
- 1991-06-03 AU AU80941/91A patent/AU652946B2/en not_active Ceased
- 1991-06-03 EP EP91910813A patent/EP0532595B1/en not_active Expired - Lifetime
- 1991-06-03 KR KR1019920703125A patent/KR100236253B1/ko not_active IP Right Cessation
- 1991-06-07 PT PT97905A patent/PT97905B/pt not_active IP Right Cessation
- 1991-06-07 IE IE194591A patent/IE80754B1/en not_active IP Right Cessation
-
1992
- 1992-12-04 US US07/949,648 patent/US5441976A/en not_active Expired - Lifetime
- 1992-12-07 NO NO92924723A patent/NO924723L/no unknown
-
1993
- 1993-05-20 NZ NZ247658A patent/NZ247658A/en unknown
- 1993-08-06 LV LVP-93-1017A patent/LV10186B/en unknown
-
1995
- 1995-06-01 US US08/457,004 patent/US5780508A/en not_active Expired - Fee Related
-
1997
- 1997-05-08 HK HK62597A patent/HK62597A/xx not_active IP Right Cessation
- 1997-10-30 LV LVP-97-219A patent/LV11985B/en unknown
Also Published As
Publication number | Publication date |
---|---|
LV11985A (lv) | 1998-03-20 |
DE69122961D1 (de) | 1996-12-05 |
JP3204320B2 (ja) | 2001-09-04 |
DE69122961T2 (de) | 1997-03-13 |
DK0532595T3 (da) | 1997-04-07 |
CA2083274A1 (en) | 1991-12-09 |
EP0532595B1 (en) | 1996-10-30 |
IL98310A0 (en) | 1992-06-21 |
AU8094191A (en) | 1991-12-31 |
NZ247658A (en) | 2000-07-28 |
US5780508A (en) | 1998-07-14 |
HU9203871D0 (en) | 1993-03-29 |
LV11985B (en) | 1998-06-20 |
IL98310A (en) | 1996-08-04 |
IE911945A1 (en) | 1991-12-18 |
US5441976A (en) | 1995-08-15 |
PT97905A (pt) | 1992-03-31 |
WO1991018594A1 (en) | 1991-12-12 |
HU215920B (hu) | 1999-03-29 |
KR100236253B1 (ko) | 1999-12-15 |
JPH05507705A (ja) | 1993-11-04 |
HUT70055A (en) | 1995-09-28 |
IE80754B1 (en) | 1999-01-13 |
NO924723D0 (no) | 1992-12-07 |
LV10186A (lv) | 1994-10-20 |
HK62597A (en) | 1997-05-16 |
NO924723L (no) | 1992-12-07 |
ATE144705T1 (de) | 1996-11-15 |
LV10186B (en) | 1995-08-20 |
CA2083274C (en) | 2002-05-28 |
SG49736A1 (en) | 1998-06-15 |
RU2119793C1 (ru) | 1998-10-10 |
AU652946B2 (en) | 1994-09-15 |
EP0532595A1 (en) | 1993-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT97905B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina | |
US5258371A (en) | Method to reduce connective tissue destruction | |
DE69213256T2 (de) | Organische salze von n, n'-diacetylcystin | |
US4305958A (en) | Cysteine derivatives | |
JP2001508804A (ja) | 代謝を増強し酸化ストレスを防止するための食物組成物 | |
PT867179E (pt) | Composicao de esteres de l-dopa | |
JPH06183973A (ja) | L−2−オキソチアゾリジン−4−カルボキシレートのエステルを用いるグルタチオン細胞内合成の刺激方法 | |
GB2211407A (en) | Monokine inhibitors | |
PT98121B (pt) | Processo para a preparacao de novos 3,3'-ditio-bis (acidos propionicos) e seus esteres e de composicoes farmaceuticas que os contem | |
IE62333B1 (en) | Use of aromatic carboxylic acid amides | |
US4200647A (en) | Vitamin A compositions to treat rheumatic disease | |
US6825232B2 (en) | Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders | |
JPS61251622A (ja) | 胃粘膜 細胞を保護するアスピリン含有組成物 | |
EP0163683A1 (en) | Chromone-2-carboxilic acid derivatives as cardiovascular agents | |
IE51737B1 (en) | Topical formulations of 3-deazaadenosine | |
LT4006B (en) | The pharmacological use of certain cystine derivatives | |
NZ238306A (en) | Pharmaceutical compositions containing certain cystine derivatives. | |
US20030232858A1 (en) | Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth | |
JPH02502189A (ja) | システインの新規な誘導体 | |
US3898338A (en) | 1,4-Bis-acylpiperazine mucolytic process | |
US20180169085A1 (en) | Combination Therapy for Hemorrhagic Injury | |
EP4247350A1 (en) | Composition for use in a method for the prevention and treatment of diseases of the respiratory system | |
JP2015512439A (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
JPS5973515A (ja) | 肝障害抑制剤 | |
CS209860B2 (cs) | Způsob výroby nových derivátů aminokyselin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB1A | Laying open of patent application |
Effective date: 19911118 |
|
FG3A | Patent granted, date of granting |
Effective date: 19980723 |
|
MM3A | Annulment or lapse |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20050124 |